1. Spotlight on Monoclonal Antibodies in Multiple Myeloma

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Overview

5. Daratumumab Phase 1/2 Data

6. Elotuzumab: Phase 1/2 Data

7. mAb Combination Therapy, Early Relapse Trials Daratumumab

8. mAb Combination Therapy, Early Relapse Trials Elotuzumab

9. Limitations of Early Relapse Trials POLLUX

10. Dara/Pom/Dex in R/R MM Utility of Daratumumab Retreatment in 1st Relapse

11. Phase 3 OPTIMISMM Trial (Pom/Bort/Dex) PFS in Patients With 1 Prior Line of Therapy

12. mAb Indications in Previously Treated Patients With MM

13. APOLLO (Phase 3) Pom/Dex +/- Dara in R/R MM

14. ELOQUENT-3 Elo + Pom/Dex for R/R MM

15. Treatment After CD38-mAb Failure

16. Integrating Dara and Elo Into MM Therapy Proposed Simplified mAb Infusion Algorithm

17. Dosing Considerations

18. ALCYONE Dara + VMP for Untreated MM

19. Dara + Len/dex (D-Rd) vs Rd in Transplant-Ineligible NDMM: MAIA

20. Open Questions

21. Future Directions

22. Abbreviations

23. Abbreviations (cont)